Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Parkinson’s disease (PD) is a progressive neurodegenerative, dopamine deficiency disorder. The main therapeutic strategies for PD treatment relies on dopamine precursors (levodopa), inhibition of dopamine metabolism (monoamine oxidase [MAO] B and catechol-O-methyl transferase inhibitors), and dopami...

Full description

Saved in:
Bibliographic Details
Main Authors: Lecht, Shimon, Haroutiunian, Simon, Hoffman, Amnon, Lazarovici, Philip
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2007
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2386362/
https://ncbi.nlm.nih.gov/pubmed/18488080
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items